UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 


 

FORM 8-K

 

CURRENT REPORT

 

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 


 

Date of Report (Date of earliest event reported):  May 6, 2014

 

BOSTON SCIENTIFIC CORPORATION

(Exact name of registrant as specified in its charter)

 

DELAWARE

 

1-11083

 

04-2695240

(State or other

 

(Commission

 

(IRS employer

jurisdiction of

 

file number)

 

identification no.)

incorporation)

 

 

 

 

 

One Boston Scientific Place, Natick, Massachusetts

 

01760-1537

(Address of principal executive offices)

 

(Zip code)

 

Registrant’s telephone number, including area code:  (508) 650-8000

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

o  Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 



 

ITEM 5.07.                               SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS.

 

(a)                                 Boston Scientific Corporation (the “Company”) held its 2014 Annual Meeting of Stockholders (the “Annual Meeting”) on May 6, 2014 at its Corporate Headquarters located in Natick, Massachusetts.

 

(b)                                 The final voting results on each of the matters submitted to a vote of stockholders at the Annual Meeting are set forth below.

 

(1)                     All eleven director nominees were elected to the Company’s Board of Directors for a one-year term to hold office until the Company’s 2015 Annual Meeting of Stockholders and until their successors have been elected and qualified.

 

Nominee

 

For

 

Withheld

 

Broker Non-Votes

Bruce L. Byrnes

 

1,060,505,874

 

7,245,394

 

72,859,222

Nelda J. Connors

 

1,059,563,807

 

8,187,461

 

72,859,222

Kristina M. Johnson

 

1,062,539,427

 

5,211,841

 

72,859,222

Edward J. Ludwig

 

1,063,292,389

 

4,458,879

 

72,859,222

Michael F. Mahoney

 

1,056,550,951

 

11,200,317

 

72,859,222

Ernest Mario

 

955,297,133

 

112,454,135

 

72,859,222

N.J. Nicholas, Jr.

 

1,051,151,453

 

16,599,815

 

72,859,222

Pete M. Nicholas

 

1,050,003,145

 

17,748,123

 

72,859,222

Uwe E. Reinhardt

 

1,053,874,765

 

13,876,503

 

72,859,222

David J. Roux

 

1,063,362,956

 

4,388,312

 

72,859,222

John E. Sununu

 

1,059,092,516

 

8,658,752

 

72,859,222

 

(2)                     The advisory vote on the compensation for the Company’s “Named Executive Officers” as disclosed in the Company’s proxy statement for the Annual Meeting (the “Proxy Statement”) was approved.

 

For

 

Against

 

Abstain

 

Broker Non-Votes

953,886,735

 

107,834,346

 

6,030,187

 

72,859,222

 

(3)                     The amendment and restatement of the Company’s 2006 Global Employee Stock Ownership Plan, as amended, was approved.

 

For

 

Against

 

Abstain

 

Broker Non-Votes

1,052,420,894

 

8,758,738

 

6,571,636

 

72,859,222

 

(4)                     The appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the 2014 fiscal year was ratified.

 

For

 

Against

 

Abstain

 

Broker Non-Votes

1,128,909,538

 

9,567,795

 

2,133,157

 

N/A

 

(5)                     The stockholder proposal regarding accountability in animal experimentation as described in the

 

2



 

Proxy Statement was not approved.

 

For

 

Against

 

Abstain

 

Broker Non-Votes

40,915,396

 

786,785,293

 

240,050,579

 

72,859,222

 

3



 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

BOSTON SCIENTIFIC CORPORATION

 

 

 

 

 

 

Date:  May 8, 2014

By:

/s/ Vance R. Brown

 

Vance R. Brown

 

Vice President and Chief Corporate Counsel

 

4